Tag - cystic fibrosis

Developments

Eloxx Pharma IND cleared for Phase 2 cystic fibrosis trial

Eloxx Pharmaceuticals (NASDAQ:ELOX) reported that the FDA cleared its IND for a Phase 2 trial of ELX-02 in patients with cystic fibrosis (CF). ELX-02 is a small molecule designed to restore production of CF...

July 31, 2019

Developments

Translate Bio reports interim Phase 1/2 cystic fibrosis trial data

Translate Bio (NASDAQ:TBIO) reported interim results from its Phase 1/2 clinical trial of MRT5005 in patients with cystic fibrosis (CF). MRT5005 is inhaled to deliver the gene that encodes functional CF transmembrane...

July 31, 2019

Developments

Proteostasis doses first patient in Phase 2 cystic fibrosis trial

Proteostasis Therapeutics (NASDAQ: PTI) dosed the first patient in a 28-day Phase 2 trial evaluating combinations of PTI-801, PTI-808 and PTI-428 for the treatment of cystic fibrosis (CF). CF is caused by a mutation in...

July 25, 2019

Markets

Brookline starts Arcturus Therapeutics at buy; PT $25

Brookline Capital Markets launched coverage of Arcturus Therapeutics (NASDAQ:ARCT) with a “buy” rating and price target of $25. The stock closed at $11.80 on July 24. Arcturus is developing RNA-based therapies...

July 25, 2019

Developments

Aridis Pharma gets EMA orphan drug designation for CF drug

Aridis Pharmaceuticals (NASDAQ:ARDS) received European Medicines Agency (EMA) orphan drug designation for AR-501 for the treatment of lung infections in patients with cystic fibrosis (CF). AR-501 is an inhaled...

July 19, 2019

Feature

Concert starts multiple dose trial with CF drug

By Len Zehr Concert Pharmaceuticals (NASDAQ:CNCE), which is modifying known drugs with its deuterium technology, last week initiated a multiple ascending dose Phase 1 trial with healthy volunteers of its next generation...

November 17, 2015

Tag - cystic fibrosis

Eloxx Pharma IND cleared for Phase 2 cystic fibrosis trial

Translate Bio reports interim Phase 1/2 cystic fibrosis trial data

Proteostasis doses first patient in Phase 2 cystic fibrosis trial

Brookline starts Arcturus Therapeutics at buy; PT $25

Aridis Pharma gets EMA orphan drug designation for CF drug

Concert starts multiple dose trial with CF drug

General

More